Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Bristol-Myers Squibb (BMY) Gets a Hold from RBC Capital

Tipranks - Tipranks - Sat Apr 11, 6:18AM CDT

RBC Capital analyst Trung Huynh maintained a Hold rating on Bristol-Myers Squibb today and set a price target of $60.00.

Easter Sale - 70% Off TipRanks

According to TipRanks, Huynh is a 5-star analyst with an average return of 27.1% and a 74.40% success rate. Huynh covers the Healthcare sector, focusing on stocks such as Merck & Company, Eli Lilly & Co, and Bristol-Myers Squibb.

In addition to RBC Capital, Bristol-Myers Squibb also received a Hold from Cantor Fitzgerald’s Carter Gould in a report issued on April 8. However, yesterday, Bank of America Securities maintained a Buy rating on Bristol-Myers Squibb (NYSE: BMY).

See today’s best-performing stocks on TipRanks >>

Based on Bristol-Myers Squibb’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $12.5 billion and a net profit of $1.09 billion. In comparison, last year the company earned a revenue of $12.34 billion and had a net profit of $72 million

Read More on BMY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).